<h2 id="what-is-propofol-">What is Propofol? <sup id="fnref:1" role="doc-noteref"><a href="#fn:1" class="footnote" rel="footnote">1</a></sup><sup id="fnref:2" role="doc-noteref"><a href="#fn:2" class="footnote" rel="footnote">2</a></sup></h2>
<ul>
  <li>Sedative agent for induction and maintenance of anesthesia.</li>
  <li>Rapid redistribution allows brief, deep sedation (e.g., joint reductions, cardioversions, ECT).</li>
</ul>
<h2 id="mechanism-of-action--pharmacokinetics-">Mechanism of Action &amp; Pharmacokinetics <sup id="fnref:1:1" role="doc-noteref"><a href="#fn:1" class="footnote" rel="footnote">1</a></sup><sup id="fnref:2:1" role="doc-noteref"><a href="#fn:2" class="footnote" rel="footnote">2</a></sup></h2>
<ul>
  <li>Exact mechanism is not fully understood, likely potentiates GABA receptors.</li>
  <li>Highly protein-bound and lipophilic, metabolized in the liver via conjugation, and excreted through the renal system.</li>
  <li><strong>Half-life:</strong>
    <ul>
      <li>Redistribution: 2 - 8 minutes.</li>
      <li>Elimination: 4 - 7 hours.</li>
    </ul>
  </li>
</ul>
<h2 id="pharmacodynamics-">Pharmacodynamics <sup id="fnref:1:2" role="doc-noteref"><a href="#fn:1" class="footnote" rel="footnote">1</a></sup><sup id="fnref:2:2" role="doc-noteref"><a href="#fn:2" class="footnote" rel="footnote">2</a></sup></h2>
<h3 id="cardiovascular">Cardiovascular</h3>
<ul>
  <li>Decreases arterial blood pressure by reducing systemic vascular resistance through arterial and venous vasodilation.</li>
  <li>Reduces preload, afterload, and cardiac output.</li>
  <li>Inhibits the baroreceptor response, preventing the compensatory increase in heart rate typically seen with hypotension.</li>
</ul>
<h3 id="respiratory">Respiratory</h3>
<ul>
  <li>Depresses respiratory drive, leading to dose-dependent apnea</li>
  <li>Inhibits hypoxia-mediated drive to breathe and reduces the ventilatory response to elevated CO2.</li>
  <li>Suppresses upper airway reflexes, facilitating tracheal intubation and LMA placement.</li>
  <li>Decreases tidal volume while increasing respiratory rate, with minimal impact on minute ventilation.</li>
</ul>
<h3 id="central-nervous-system">Central Nervous System</h3>
<ul>
  <li>Decreases cerebral metabolic rate (CMR), cerebral blood flow (CBF), intracranial pressure (ICP), and intraocular pressure (IOP).</li>
  <li>Exhibits anticonvulsant properties and can be used in the treatment of refractory seizures.</li>
  <li>May result in a critical decrease in cerebral perfusion pressure (CPP) in patients with raised ICP, particularly if mean arterial pressure (MAP) drops significantly.</li>
</ul>
<h2 id="indications-">Indications <sup id="fnref:1:3" role="doc-noteref"><a href="#fn:1" class="footnote" rel="footnote">1</a></sup><sup id="fnref:2:3" role="doc-noteref"><a href="#fn:2" class="footnote" rel="footnote">2</a></sup></h2>
<h3 id="anesthetic-indications">Anesthetic Indications</h3>
<ul>
  <li>Induction and maintenance of general anesthesia (TIVA technique).</li>
  <li>Sedation during procedures (e.g., mechanical ventilation, intubation).</li>
</ul>
<h3 id="other-indications">Other Indications</h3>
<ul>
  <li>Treatment of refractory seizures.</li>
  <li>Treatment of refractory postoperative nausea and vomiting.</li>
</ul>
<h2 id="dosage-">Dosage <sup id="fnref:2:4" role="doc-noteref"><a href="#fn:2" class="footnote" rel="footnote">2</a></sup></h2>
<ul>
  <li><strong>Induction Dose:</strong> 1.5 - 2.5 mg/kg IV; reduced to 1 - 2 mg/kg in patients premedicated with opioids or benzodiazepines. Children may require higher induction doses (up to ~4 mg/kg).</li>
  <li><strong>Maintenance Dose:</strong> 20 - 200 µg/kg/min IV infusion. See <a href="TIVA.md">TIVA</a>.</li>
  <li><strong>Half-life:</strong> Redistribution: 2 - 8 minutes; Elimination: 4 - 7 hours.</li>
</ul>
<h2 id="complications-">Complications <sup id="fnref:1:4" role="doc-noteref"><a href="#fn:1" class="footnote" rel="footnote">1</a></sup><sup id="fnref:2:5" role="doc-noteref"><a href="#fn:2" class="footnote" rel="footnote">2</a></sup></h2>
<ul>
  <li>Pain on injection, often mitigated by co-administration of lidocaine.</li>
  <li>Hypotension, particularly in patients with reduced cardiovascular reserve or fixed cardiac output.</li>
  <li>Propofol infusion syndrome (rare but serious)</li>
  <li>QT prolongation (rare).</li>
</ul>
<h2 id="references">References</h2>
<div class="footnotes" role="doc-endnotes">
  <ol>
    <li id="fn:1" role="doc-endnote">
      <p>Folino, T.B, Muco, E., Safadi, A.O., Parks, L.J. (2022). Propofol. <em>StatPearls</em>. https://www.ncbi.nlm.nih.gov/books/NBK430884 <a href="#fnref:1" class="reversefootnote" role="doc-backlink">&#8617;</a> <a href="#fnref:1:1" class="reversefootnote" role="doc-backlink">&#8617;<sup>2</sup></a> <a href="#fnref:1:2" class="reversefootnote" role="doc-backlink">&#8617;<sup>3</sup></a> <a href="#fnref:1:3" class="reversefootnote" role="doc-backlink">&#8617;<sup>4</sup></a> <a href="#fnref:1:4" class="reversefootnote" role="doc-backlink">&#8617;<sup>5</sup></a></p>
    </li>
    <li id="fn:2" role="doc-endnote">
      <p>Birdi T, Sullivan P. Ottawa Anesthesia Primer. Toronto, Ontario: Echo Book Publishing; 2012. <a href="#fnref:2" class="reversefootnote" role="doc-backlink">&#8617;</a> <a href="#fnref:2:1" class="reversefootnote" role="doc-backlink">&#8617;<sup>2</sup></a> <a href="#fnref:2:2" class="reversefootnote" role="doc-backlink">&#8617;<sup>3</sup></a> <a href="#fnref:2:3" class="reversefootnote" role="doc-backlink">&#8617;<sup>4</sup></a> <a href="#fnref:2:4" class="reversefootnote" role="doc-backlink">&#8617;<sup>5</sup></a> <a href="#fnref:2:5" class="reversefootnote" role="doc-backlink">&#8617;<sup>6</sup></a></p>
    </li>
  </ol>
</div>